NCT04560972View on ClinicalTrials.gov

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

March 9, 2026

Study Completion Date

March 9, 2026

Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Protein Phosphatase 2A Inhibitor LB-100

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT04560972 - LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter